Pfizer: The Opichron-specific vaccine will be ready in March

According to CNBC, Pfizer CEO Albert Bourla said that the company's Semikron-specific vaccine will be ready in March this year, although it is still uncertain whether a specific vaccine is needed or it is still unclear how to use the Omiljung vaccine.

Since cases of the Omiljung variant were first reported late last year, experts have been concerned about whether existing vaccines will be able to withstand huge viral mutations. While vaccine manufacturers are confident that vaccines can prevent serious illness and death, they are not too sure about their ability to reduce symptomatic infections.

On December 8, 2021, preliminary research in Nature suggested that the Omiljung variant can avoid neutralizing antibodies that are expected to block the virus in the early stages of infection. So the world is on the path of boosting doses, increasing levels of neutralizing antibodies to combat new coronavirus variants.

According to CNBC, real data compiled by the UK's Health Security Agency concluded that the Pfizer and Moderna vaccines were only 10% effective in preventing symptomatic infections after 20 weeks after the second dose of vaccination, although the first two doses of the vaccine continued to prevent serious diseases. In addition, boosting doses can increase the effectiveness of the vaccine in preventing symptomatic infections to 75%.

It is reported that when it comes to Pfizer's vaccine, Bourla said that the Omicron vaccine will also target other virus variants. Previous reports from South Africa suggest that infections could peak before the end of 2021, and other regions could also peak soon. As a result, Pfizer could target a vaccine that would better prevent infections. Meanwhile, Pfizer has begun producing some doses of the Opichron-specific vaccine for countries that may need the Opmi-Keron vaccine in the first place.

Forward-looking Economist APP Information Group